908 Devices Inc. (MASS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
908 Devices NASDAQ: MASS is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion.
908 Devices Q2: Another Solid Report
908 Devices delivered another revenue beat in Q2, as device sales continued to shine. Q2 revenues grew 23% year-over-year to $16.07 million, with product revenue up nearly 35.5% and the installed base expanding 23%. Management raised 2026 revenue guidance to $68–$70 million, implying 21–25% growth, while operating and net losses narrowed.
908 Devices: Mission Critical Devices Drive Growth
908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M.
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
908 Devices Inc. (MASS) Q2 2026 Earnings Call Transcript
908 Devices Q2 Earnings Call Highlights
908 Devices NASDAQ: MASS reported second-quarter revenue growth of 23% as demand from U.S. state and local government customers, FTIR product shipments and its recently acquired NIRLab platform supported results. The company also raised the low end of its full-year revenue outlook while continuing to exclude potential revenue from the U.S. military's AVCAD program from its core guidance.
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.18 per share a year ago.
908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
908 Devices (MASS) Upgraded to Buy: Here's Why
908 Devices (MASS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
908 Devices Looking Better Now (Rating Upgrade)
908 Devices (MASS) delivered strong Q1 results, raising full-year revenue guidance after a strategic acquisition in narcotics detection. Adjusted gross margins improved nearly three percentage points to 57%, and operating cash flow turned positive. The company has a solid balance sheet with nearly $100 million in cash post-acquisition and is debt free, while trading at a reasonable valuation.
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) came out with a quarterly loss of $0.15 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.22 per share a year ago.
